Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 06 2021
Historique:
revised: 07 10 2020
received: 20 06 2020
accepted: 22 10 2020
pubmed: 12 11 2020
medline: 12 10 2021
entrez: 11 11 2020
Statut: ppublish

Résumé

To compare the predictive performances of the prewiring, postwiring MI-SYNTAX scores, prewiring, and postwiring Updated Logistic Clinical SYNTAX score (LCSS) for 2-year all-cause mortality post percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) patients. In patients with STEMI and undergoing primary PCI, coronary stenosis(es) distal to the culprit lesion is often observed after the restoration of coronary flow. To address comprehensively the complex coronary anatomy in these patients, prewiring and postwiring MI-SYNTAX scores have been reported in the literature. Furthermore, to enable individualized risk estimation for long-term all-cause mortality, the Updated LCSS has been developed by combining the anatomical SYNTAX score and clinical factors. In the randomized GLOBAL LEADERS trial, anatomical SYNTAX score analysis was performed by an independent angiographic corelab for the first 4,000 consecutive patients as a prespecified analysis; of these, 545 presented with STEMI. The efficacy of the mortality predictions of the four scores at 2 years were evaluated based on their discrimination and calibration abilities. Complete data was available in 512 patients (93.9%). When the patients were stratified into two groups based on the median of the scores, the prewiring and postwiring Updated LCSSs demonstrated that the high-score groups were associated with higher rates of 2-year all-cause mortality compared to the low-score groups (6.6 vs. 1.2%; log-rank p = .001 and 6.6 vs. 1.2%; log-rank p = .001, respectively). There were no statistically significant differences for predicting the mortality between the prewiring (area under the curve [AUC] 0.625), postwiring MI-SYNTAX score (AUC 0.614), prewiring (AUC 0.755), and postwiring Updated LCSS (AUC 0.757). In the integrated discrimination improvement (IDI), the prewiring MI-SYNTAX score had a better discrimination for the mortality than the postwiring MI-SYNTAX score (IDI -0.0082; p = .029). The four scores had acceptable calibration abilities for 2-year all-cause mortality. The prewiring Updated LCSS predicts long-term all-cause mortality with clearly useful discrimination and acceptable calibration. Since the postwiring MI-SYNTAX score does not improve mortality prediction, the prewiring MI-SYNTAX score may be preferred for the 2-year mortality prediction using the Updated LCSS.

Sections du résumé

OBJECTIVES
To compare the predictive performances of the prewiring, postwiring MI-SYNTAX scores, prewiring, and postwiring Updated Logistic Clinical SYNTAX score (LCSS) for 2-year all-cause mortality post percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) patients.
BACKGROUND
In patients with STEMI and undergoing primary PCI, coronary stenosis(es) distal to the culprit lesion is often observed after the restoration of coronary flow. To address comprehensively the complex coronary anatomy in these patients, prewiring and postwiring MI-SYNTAX scores have been reported in the literature. Furthermore, to enable individualized risk estimation for long-term all-cause mortality, the Updated LCSS has been developed by combining the anatomical SYNTAX score and clinical factors.
METHODS
In the randomized GLOBAL LEADERS trial, anatomical SYNTAX score analysis was performed by an independent angiographic corelab for the first 4,000 consecutive patients as a prespecified analysis; of these, 545 presented with STEMI. The efficacy of the mortality predictions of the four scores at 2 years were evaluated based on their discrimination and calibration abilities.
RESULTS
Complete data was available in 512 patients (93.9%). When the patients were stratified into two groups based on the median of the scores, the prewiring and postwiring Updated LCSSs demonstrated that the high-score groups were associated with higher rates of 2-year all-cause mortality compared to the low-score groups (6.6 vs. 1.2%; log-rank p = .001 and 6.6 vs. 1.2%; log-rank p = .001, respectively). There were no statistically significant differences for predicting the mortality between the prewiring (area under the curve [AUC] 0.625), postwiring MI-SYNTAX score (AUC 0.614), prewiring (AUC 0.755), and postwiring Updated LCSS (AUC 0.757). In the integrated discrimination improvement (IDI), the prewiring MI-SYNTAX score had a better discrimination for the mortality than the postwiring MI-SYNTAX score (IDI -0.0082; p = .029). The four scores had acceptable calibration abilities for 2-year all-cause mortality.
CONCLUSIONS
The prewiring Updated LCSS predicts long-term all-cause mortality with clearly useful discrimination and acceptable calibration. Since the postwiring MI-SYNTAX score does not improve mortality prediction, the prewiring MI-SYNTAX score may be preferred for the 2-year mortality prediction using the Updated LCSS.

Identifiants

pubmed: 33175478
doi: 10.1002/ccd.29383
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

E919-E928

Subventions

Organisme : AstraZeneca
Organisme : Biosensors International Group

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219-227.
Knuuti J, Wijns W, Saraste A, et al. ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
Serruys PW, Chichareon P, Modolo R, et al. The SYNTAX score on its way out or towards artificial intelligence: part I. EuroIntervention. 2020;16:44-59.
Serruys PW, Chichareon P, Modolo R, et al. The SYNTAX score on its way out or towards artificial intelligence: part II. EuroIntervention. 2020;16:60-75.
Magro M, Nauta S, Simsek C, et al. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: the MI SYNTAXscore study. Am Heart J. 2011;161(4):771-781.
Menon V, Hochman JS, Stebbins A, et al. Lack of progress in cardiogenic shock: lessons from the GUSTO trials. Eur Heart J. 2000;21(23):1928-1936.
Farooq V, Vergouwe Y, Raber L, et al. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the logistic clinical SYNTAX score. Eur Heart J. 2012;33(24):3098-3104.
Farooq V, Vergouwe Y, Genereux P, et al. Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary intervention: validation of the logistic clinical SYNTAX (synergy between percutaneous coronary interventions with taxus and cardiac surgery) score. JACC Cardiovasc Interv. 2013;6(7):737-745.
Capodanno D, Giacoppo D, Dipasqua F, et al. Usefulness of the logistic clinical SYNTAX score for predicting 1-year mortality in patients undergoing percutaneous coronary intervention of the left main coronary artery. Catheter Cardiovasc Interv. 2013;82(4):E446-E452.
Iqbal J, Vergouwe Y, Bourantas CV, et al. Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. JACC Cardiovasc Interv. 2014;7(5):464-470.
Chichareon P, Onuma Y, van Klaveren D, et al. Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention. 2019;15(6):e539-e546.
Vranckx P, Valgimigli M, Juni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940-949.
Vranckx P, Valgimigli M, Windecker S, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2016;12(10):1239-1245.
Magro M, Raber L, Heg D, et al. The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: a substudy of the COMFORTABLE AMI trial. Int J Cardiol. 2014;175(2):314-322.
Hicks KA, Mahaffey KW, Mehran R, et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137(9):961-972.
Rosner B, Glynn RJ, Lee ML. The Wilcoxon signed rank test for paired comparisons of clustered data. Biometrics. 2006;62(1):185-192.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845.
Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: Users' guides to the medical literature. JAMA. 2017;318(14):1377-1384.
Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172. discussion 207-12.
Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925-1931.
Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115(1):92-106.
Gronnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal. 1996;2(4):315-328.
Suryapranata H, Zijlstra F, MacLeod DC, van den Brand M, de Feyter PJ, Serruys PW. Predictive value of reactive hyperemic response on reperfusion on recovery of regional myocardial function after coronary angioplasty in acute myocardial infarction. Circulation. 1994;89(3):1109-1117.
Bagai A, Dangas GD, Stone GW, Granger CB. Reperfusion strategies in acute coronary syndromes. Circ Res. 2014;114(12):1918-1928.
Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50(7):573-583.

Auteurs

Hideyuki Kawashima (H)

Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.

Hironori Hara (H)

Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.

Rutao Wang (R)

Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.
Department of Cardiology, Radboudumc, Nijmegen, Netherlands.

Masafumi Ono (M)

Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.

Chao Gao (C)

Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.
Department of Cardiology, Radboudumc, Nijmegen, Netherlands.

Kuniaki Takahashi (K)

Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Harry Suryapranata (H)

Department of Cardiology, Radboudumc, Nijmegen, Netherlands.

Simon Walsh (S)

Department of Cardiology Belfast Health and Social Care Trust, Belfast, UK.

James Cotton (J)

Heart and Lung Centre, New Cross Hospital, Wolverhampton, UK.

Didier Carrie (D)

Department of Cardiology, Rangueil hospital, Paul Sabatier University Toulouse 3, Toulouse, France.

Manel Sabate (M)

Clinic Hospital Barcelona, Barcelona, Spain.

Clemens Steinwender (C)

Department of Cardiology Kepler University Hospital Linz Medical Faculty, Johannes Kepler University Linz, Linz, Austria.

Gregor Leibundgut (G)

Department of Cardiology, Kantonsspital Baselland, Standort Liestal, Liestal, Switzerland.

Joanna Wykrzykowska (J)

Royal Blackburn Hospital, Blackburn, UK.

Christian Hamm (C)

Kerckhoff Heart Center, Campus University of Giessen, Bad Nauheim, Germany.

Peter Jüni (P)

Université Paris-Diderot, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, INSERM U-1148, FACT (French Alliance for Cardiovascular Trials) Paris, France.

Pascal Vranckx (P)

Jessa Ziekenhuis, Faculty of Medicine and Life Sciences at the Hasselt University, Hasselt, Belgium.

Marco Valgimigli (M)

Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.

Stephan Windecker (S)

Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.

Robbert J de Winter (RJ)

Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Faisal Sharif (F)

Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.

Yoshinobu Onuma (Y)

Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.

Patrick W Serruys (PW)

Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.
NHLI, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH